Genetic studies implicate the oncogenic transcription factor Forkhead Box M1 (FOXM1) as a
potential therapeutic target in high-grade serous ovarian cancer (HGSOC). We evaluated …

FOXM1 is a key transcriptional regulator involved in various biological processes in
mammals, including carbohydrate and lipid metabolism, aging, immune regulation …

Forkhead box protein M1 (FOXM1) is often overexpressed in human cancers and strongly
associated with therapy resistance and less good patient survival. The chemotherapy …

For cancer therapy, the focus is now on targeting the chemotherapy drugs to cancer cells
without damaging other normal cells. The new materials based on bio-compatible magnetic …

Ewing sarcoma (EwS), a highly aggressive malignancy affecting children and young adults,
is primarily driven by a distinctive oncogenic fusion, the EWSR1‐ETS, whose activity is a key …

FOXM1 is the “Achilles' heel” of cancers and hence the potential therapeutic target for
anticancer drug discovery. In this work, we selected high affinity peptides against the protein …

Melanoma poses a significant challenge to patients due to its aggressive nature and limited
treatment options. Recent studies have suggested that lasalocid, a feed additive ionophore …

FOXM1 is a crucial oncogenic transcription factor involved in almost all cancer hallmark
pathways across all cancer types. Our previous work had found that FOXM1 targeted …

Background: Clear cell renal cell carcinoma (ccRCC) stands as the most prevalent form of
kidney cancer, accounting for a significant proportion of malignancies affecting the kidneys …

[WITHDRAWN] Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum
of cancer therapies - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …